FDA Can Regulate Stem Cell Treatment As Drug, DC Circ. Hears

Law360, Los Angeles (March 13, 2013, 4:51 PM EDT) -- The U.S. Food and Drug Administration told the D.C. Circuit that Regenerative Sciences LLC's stem cell treatment is a drug and therefore subject to its regulations, saying a lower court had ruled correctly on the question in the drug company's suit challenging the agency's right to regulate the treatment.

In a brief filed with the D.C. Circuit Wednesday, the FDA said U.S. District Judge Rosemary M. Collyer was justified in ruling that Regenerative Sciences’ Regenexx procedure, which uses a patient's stem cells mixed with other components...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.